Answers are grounded in this paper and cite their sources.
Background The oncologic benefits of neoadjuvant chemotherapy (NAC) in advanced gastric cancer are documented, but concerns about the effect of NAC on surgical outcomes have not been well-studied. Methods This retrospective cohort evaluated non-metastatic gastric cancer (GC) patients who underwent surgery at Kaiser Permanente Mid-Atlantic and Johns Hopkins Hospitals between 2015 and 2021. Early postoperative (post-op) complications and surgical outcomes, including length of stay (LOS), readmission, and mortality within the first thirty days after surgery, were evaluated and compared between those who received NAC and underwent upfront surgery. A multivariable logistic regression model was created to evaluate the association between NAC and early post-op complications. Results A total of 226 cases were evaluated. NAC was administered in 145 patients (64.6%). Post-op complications were observed in 63 (29.7%) (29% of the NAC+ and 32% of the upfront surgery, p=0.6). Thirty-day post-op mortality was 1.9% (2.1% in the NAC+ and 1.4% in the upfront surgery, p=0.8). The median length of stay (LOS) was 7 days in the NAC+ and 6 days in the upfront surgery group (p = 0.4). The readmission rate was 12.3%, lower in the NAC+ (8%) compared to the upfront surgery group (20%) (p = 0.02). Adjusted multivariate logistic regression analysis showed that NAC administration was not associated with the rate of post-op complications (OR: 1.16, 95%CI: 0.53- 2.54; p=0.70). Conclusion Our findings suggest that NAC can be administered safely and may not adversely affect short-term surgical outcomes in gastric cancer.
No takes yet. Share an insight, caveat, or question.
Vasigh et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: